Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KRIYA 825

Next Previous
X
Search
Drug Profile

KRIYA 825

Alternative Names: KRIYA-825; VV-14295

Latest Information Update: 14 Jan 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kriya Therapeutics
  • Class Eye disorder therapies; Gene therapies; Recombinant fusion proteins
  • Mechanism of Action Complement C3 expression inhibitors; Complement C5 expression inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Dry age-related macular degeneration

Most Recent Events

  • 09 Jan 2025 Kriya Therapeutics plans a phase I/II VISION trial for Dry age-related macular degeneration in New Zealand (Intraocular) (NCT06765980)
  • 08 Jan 2024 Kriya therapeutics plans a clinical trial for Dry age-related macular degeneration in the end of 2025 (Intraocular)
  • 08 Jan 2024 Preclinical trials in Dry age-related macular degeneration in USA (Intraocular), prior to January 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top